Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if ...

Analysts estimate that Biofrontera will report an earnings per share (EPS) of $-0.83. Investors in Biofrontera are eagerly ...

US-based company Biofrontera has announced topline results from a Phase III trial evaluating its drug-device therapy, Ameluz ...

In a letter dated November 11, 2024, received on the same day, Biofrontera AG received the following notification on behalf of Deutsche Balaton Biotech AG pursuant to section 43 (1) WpHG (German ...

Biofrontera CEO Hermann Luebbert Luebbert said: “We are currently writing the study protocol based on the request of FDA, which will be followed by power calculations and discussions with ...

Biofrontera announced top-line results in its Phase 3 study of the use of Ameluz with the BF-RhodoLED lamp in the treatment of sBCC. The ...

In recent trading, Biofrontera Inc (BFRI) stock price has shown some volatility, fluctuating 26.80% over the last five trades and 14.95% over the past 30 trades. This represents a notable shift from ...

On Friday, Biofrontera Inc (BFRI) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.14 or -11.38% from the prior close of $1.23. The stock opened at $1.17 and touched a ...

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily ...

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago. These figures ...

Biofrontera announced top-line results in its Phase 3 study of the use of Ameluz with the BF-RhodoLED lamp in the treatment of sBCC. The double-blind, randomized, placebo-controlled, multi-center ...